Celyad Oncology SA (CLYYF)
USD 0.53
(-22.44%)
USD 0.53
(-22.44%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -8.45 Million EUR | 79.3% |
| 2022 | -40.85 Million EUR | -54.81% |
| 2021 | -26.39 Million EUR | -0.58% |
| 2020 | -26.23 Million EUR | 10.67% |
| 2019 | -29.37 Million EUR | 23.05% |
| 2018 | -38.17 Million EUR | 27.81% |
| 2017 | -52.87 Million EUR | -106.47% |
| 2016 | -25.6 Million EUR | 13.69% |
| 2015 | -29.67 Million EUR | -80.52% |
| 2014 | -16.43 Million EUR | -37.33% |
| 2013 | -11.96 Million EUR | -730.67% |
| 2012 | -1.44 Million EUR | 84.14% |
| 2011 | -9.08 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -3.08 Million EUR | 0.0% |
| 2023 Q2 | -5.82 Million EUR | 0.0% |
| 2023 Q4 | -4.71 Million EUR | 0.0% |
| 2022 Q4 | -12.48 Million EUR | 0.0% |
| 2022 Q2 | -6.52 Million EUR | 13.52% |
| 2022 Q1 | -7.54 Million EUR | -85.62% |
| 2022 FY | -40.85 Million EUR | -54.81% |
| 2021 Q4 | -4.06 Million EUR | 45.39% |
| 2021 Q2 | -6.1 Million EUR | 30.44% |
| 2021 Q3 | -7.44 Million EUR | -22.02% |
| 2021 Q1 | -8.77 Million EUR | -279.32% |
| 2021 FY | -26.39 Million EUR | -0.58% |
| 2020 Q2 | -16.13 Million EUR | 0.0% |
| 2020 FY | -26.23 Million EUR | 10.67% |
| 2020 Q4 | 4.89 Million EUR | 191.89% |
| 2020 Q3 | -5.32 Million EUR | 67.0% |
| 2019 FY | -29.37 Million EUR | 23.05% |
| 2019 Q1 | -7.07 Million EUR | 57.33% |
| 2019 Q2 | -17.22 Million EUR | -143.49% |
| 2019 Q4 | -17.19 Million EUR | 0.0% |
| 2018 Q2 | -15.8 Million EUR | -69.19% |
| 2018 FY | -38.17 Million EUR | 27.81% |
| 2018 Q4 | -16.57 Million EUR | 0.0% |
| 2018 Q1 | -9.34 Million EUR | 33.83% |
| 2017 FY | -52.87 Million EUR | -106.47% |
| 2017 Q4 | -14.11 Million EUR | 0.0% |
| 2017 Q2 | -12.67 Million EUR | 9.9% |
| 2017 Q1 | -14.07 Million EUR | -109.06% |
| 2016 FY | -25.6 Million EUR | 13.69% |
| 2016 Q2 | -17.24 Million EUR | -193.48% |
| 2016 Q4 | -6.73 Million EUR | 0.0% |
| 2016 Q1 | -5.87 Million EUR | 58.58% |
| 2015 Q4 | -14.18 Million EUR | -95.57% |
| 2015 FY | -29.67 Million EUR | -80.52% |
| 2015 Q3 | -7.25 Million EUR | 52.2% |
| 2015 Q2 | -15.17 Million EUR | -109.2% |
| 2015 Q1 | -7.25 Million EUR | 29.81% |
| 2014 FY | -16.43 Million EUR | -37.33% |
| 2014 Q1 | -4.1 Million EUR | 40.78% |
| 2014 Q4 | -10.33 Million EUR | -151.57% |
| 2014 Q2 | -6.41 Million EUR | -56.17% |
| 2014 Q3 | -4.1 Million EUR | 35.97% |
| 2013 Q1 | -2.98 Million EUR | 0.0% |
| 2013 Q2 | -6.01 Million EUR | -101.91% |
| 2013 Q3 | -2.98 Million EUR | 50.47% |
| 2013 Q4 | -6.93 Million EUR | -132.76% |
| 2013 FY | -11.96 Million EUR | -730.67% |
| 2012 Q3 | -538.13 Thousand EUR | 0.0% |
| 2012 Q2 | -538.13 Thousand EUR | 0.0% |
| 2012 Q1 | -538.13 Thousand EUR | 0.0% |
| 2012 FY | -1.44 Million EUR | 84.14% |
| 2012 Q4 | -2.98 Million EUR | -453.8% |
| 2011 Q1 | -2.28 Million EUR | 0.0% |
| 2011 Q2 | -2.28 Million EUR | 0.0% |
| 2011 Q3 | -2.28 Million EUR | 0.0% |
| 2011 Q4 | -538.13 Thousand EUR | 76.43% |
| 2011 FY | -9.08 Million EUR | 0.0% |
| 2010 Q4 | -2.28 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Evofem Biosciences, Inc. | -17.84 Million USD | 52.614% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -67.648% |
| CSL Limited | 3.7 Billion USD | 100.228% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 110.332% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1131.094% |
| BioStem Technologies, Inc. | -7.77 Million USD | -8.716% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -573.328% |
| Qrons Inc. | -643.67 Thousand USD | -1213.858% |
| Nascent Biotech, Inc. | -2.22 Million USD | -279.258% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 84.764% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -27.211% |
| Skye Bioscience, Inc. | -13.67 Million USD | 38.143% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1935.482% |
| Rebus Holdings, Inc. | -664 Thousand USD | -1173.645% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 46.71% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -533.279% |
| Genscript Biotech Corporation | -415.79 Million USD | 97.966% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -2070.855% |
| Adynxx, Inc. | - USD | Infinity% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 88.219% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 272.072% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -3131.242% |
| SQZ Biotechnologies Company | -75.82 Million USD | 88.847% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -196.684% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -450.568% |
| Mesoblast Limited | -84.14 Million USD | 89.95% |
| Marizyme, Inc. | -34.08 Million USD | 75.19% |
| Genus plc | 6.4 Million USD | 232.141% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 186.806% |
| Pharming Group N.V. | -4.87 Million USD | -73.315% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -325.728% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -808.007% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -1.281% |
| ContraFect Corporation | -56.88 Million USD | 85.134% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -85.675% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -503.214% |
| IMV Inc. | -38.67 Million USD | 78.131% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -207.433% |
| MultiCell Technologies, Inc. | -722.81 USD | -1169917.017% |
| ONE Bio Corp. | 13.68 Million USD | 161.813% |
| Accustem Sciences Inc. | -3.74 Million USD | -125.736% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 85.664% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -1650.707% |
| Q BioMed Inc. | -3.44 Million USD | -145.442% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 338.898% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -221.862% |
| Biomind Labs Inc. | -1 Million USD | -737.656% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 84.616% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -191.495% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -353.612% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -28135.176% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -337.595% |
| GB Sciences, Inc. | -1.42 Million USD | -495.35% |
| Alpha Cognition Inc. | -9.7 Million USD | 12.865% |
| HST Global, Inc. | -140.9 Thousand USD | -5901.831% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -651.796% |
| Halberd Corporation | -75.05 Thousand USD | -11168.488% |
| Enzolytics Inc. | -2.14 Million USD | -293.569% |
| Agentix Corp. | -1.37 Million USD | -516.509% |
| Resverlogix Corp. | -12.74 Million USD | 33.665% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -166.928% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 98.01% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -710.057% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -189.678% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -435.472% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -148.372% |
| AVAX Technologies, Inc. | 6.69 Million USD | 226.358% |
| Zenith Capital Corp. | -8.94 Million USD | 5.434% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -48444.86% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -244.436% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -4830.921% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -321.847% |
| Kadimastem Ltd | -3.04 Million USD | -178.168% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -759.405% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -4559.889% |
| LadRx Corporation | -3.82 Million USD | -121.177% |
| Cell Source, Inc. | -4.32 Million USD | -95.522% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1131.094% |
| NovAccess Global Inc. | -2.46 Million USD | -242.838% |
| Affymax, Inc. | -15.04 Million USD | 43.792% |
| Itoco Inc. | -919.14 Thousand USD | -820.099% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -99.532% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -655.764% |
| Mobile Lads Corp. | -554.55 Thousand USD | -1425.02% |
| CytoDyn Inc. | -18.05 Million USD | 53.168% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -33499.523% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -3742.728% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -1397.548% |
| SYBLEU INC | -149.18 Thousand USD | -5568.99% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -365.612% |
| International Stem Cell Corporation | -663 Thousand USD | -1175.566% |
| Bioxytran, Inc. | -3.82 Million USD | -121.379% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -15965.729% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -41478.171% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 76.681% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -422.682% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -1049.307% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -171.842% |
| Neutra Corp. | -229.48 Thousand USD | -3585.192% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 51.782% |
| PureTech Health plc | -146.19 Million USD | 94.215% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 60.649% |
| IXICO plc | -1.43 Million USD | -488.518% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 10.895% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 93.057% |
| CSL Limited | 3.81 Billion USD | 100.222% |
| Cellectis S.A. | -108.85 Million USD | 92.231% |